Answers are grounded in this paper and cite their sources.
Retrospective review identifies elevated soluble IL-2 receptor in neurotoxic myositis patients, suggesting new treatment strategies.
e14536 Background: Immune checkpoint inhibitors (ICIs) are used to treat a variety of cancer types, including melanoma, lung cancer, and breast cancer. Approximately 1-5% of patients receiving ICIs develop neurotoxicity (N-TOX). N-TOX is driven by a loss of immune tolerance, leading to aberrant activation of T-cells, astrocytes, and microglia. There is a need to better understand the pro-inflammatory milieu in N-TOX to facilitate novel treatment strategies for treatment. Therefore, we performed a retrospective review in a single institution in patients who developed N-TOX to better understand this patient population. Methods: We conducted a retrospective study of cytokine samples (CSF and/or serum) from 33 patients who developed N-TOX after ICI therapy at Moffitt Cancer Center between 2023 and 2025. Cytokine-13 panels (ARUP Laboratories, Utah) were obtained in serum only (N = 15), CSF only (N = 13), or both serum and CSF (N = 5). Results: Primary cancer types were melanoma (N = 9), lung (N = 5), renal (N = 3), head/neck (N = 3), thyroid (N = 2), urothelial, cervical, endometrial (N = 1), Merkel cell, penile, appendiceal, breast, sarcoma, liver, esophageal, and gastric (all N = 1). N-TOX syndromes included myositis (N = 17), encephalitis (N = 9), neuropathy (N = 8), myasthenia gravis (N = 2), meningitis (N = 1), and demyelinating disease (N = 1). In our cohort group, serum cytokine analysis demonstrated elevated IL-10 (10.7 +/- 5.6 pg/ml, reference < 2.8 pg/ml, p = 0.003) without significant changes in other serum cytokines. Of note, 80% of serum cytokines were collected after initiation of steroids. CSF cytokine analysis did not demonstrate any significant elevation in cytokine levels. Subgroup analysis of N-TOX myositis patients showed a significant elevation in serum sIL2R (1203 +/- 307 pg/ml, reference 175-858 pg/ml, p = 0.024) without elevation in serum interferon gamma. Subgroup analysis of N-TOX neuropathy and N-TOX encephalitis patients did not show any significant elevation in serum or CSF cytokine levels, respectively. Conclusions: Serum sIL2R was elevated in selected N-TOX patients with myositis, which suggests that therapeutic strategies to influence this cytokine or its downstream substrates may be effective. We are currently undertaking a prospective cohort with muscle biopsies to better understand this association. The serum IL-10 elevation is an anti-inflammatory response likely confounded by treatment effect.
No takes yet. Share an insight, caveat, or question.
Jaffer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: